Literature DB >> 31762336

Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.

Alvise Berti1,2, Sara Boukhlal3, Matthieu Groh4, Divi Cornec3.   

Abstract

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) usually occurs in patients with late-onset asthma and sustained peripheral blood eosinophilia and classically presents with a clinical multifaceted spectrum of manifestations, which may vary at the different stages of the natural history of the disease.Areas covered: We reviewed EGPA clinical presentation, focusing on clinical manifestations at three different phases of the disease: 1/before the development of overt vasculitis, 2/at vasculitis diagnosis and 3/during the long-term follow-up. An update on current classification criteria and recent therapeutic advances has been provided as well.Expert opinion: Asthma, chronic rhinosinusitis and blood eosinophilia could anticipate the overt vasculitis for years. An atopic background may be present in a subset of patients (25-30%), while ANCA presence varies between 10 and 40%. Systemic vasculitis rapidly occurs and clinical features demonstrating vasculitis processes (neuropathy, purpura, scleritis, alveolar hemorrhage and glomerulonephritis) develop along with systemic symptoms (50%). After vasculitis resolution, asthma remains severe in up to 50% of patients and incidence of isolated-asthma and rhinosinus exacerbations remains constantly high. Different sets of classification criteria have been published so far, and DCVAS diagnostic criteria will be presented soon. Interleukin-5 blockers seem to be promising to control the disease and to spare corticosteroids.

Entities:  

Keywords:  ANCA-associated vasculitis; Churg-Strauss; EGPA; Interleukin-5; Severe/uncontrolled asthma; eosinophilic asthma; eosinophilic granulomatosis with polyangiitis; long-term outcomes; mepolizumab; vasculitis

Mesh:

Substances:

Year:  2020        PMID: 31762336     DOI: 10.1080/1744666X.2019.1697678

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

1.  Eosinophilic Granulomatosis with Polyangiitis Presenting as Unilateral Acute Anterior Ischaemic Optic Neuropathy.

Authors:  Anthony Fong; Shahzada Ahmed; Satheesh Ramalingam; Rachel M Brown; Lorraine Harper; Susan P Mollan
Journal:  Neuroophthalmology       Date:  2020-06-25

2.  Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Jing Xiao; Shaohua Lu; Xufei Wang; Mengdi Liang; Cong Dong; Xiaoxian Zhang; Minzhi Qiu; Changxing Ou; Xiaoyin Zeng; Yanting Lan; Longbo Hu; Long Tan; Tao Peng; Qingling Zhang; Fei Long
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 3.  The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.

Authors:  Carlo Lombardi; Alvise Berti; Marcello Cottini
Journal:  Curr Res Immunol       Date:  2022-03-21

4.  Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.

Authors:  Shunya Tanaka; Taisuke Tsuji; Shinsuke Shiotsu; Tatsuya Yuba; Noriya Hiraoka
Journal:  Cureus       Date:  2022-05-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.